{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T09:17:12Z","timestamp":1716455832652},"reference-count":25,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2010,11,18]],"date-time":"2010-11-18T00:00:00Z","timestamp":1290038400000},"content-version":"vor","delay-in-days":17,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Cardiology"],"published-print":{"date-parts":[[2010,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background:<\/jats:title><jats:p>The usage of platelet glycoprotein (GP) IIb\/IIIa receptor inhibitors improves the outcome during high\u2010risk percutaneous coronary interventions (PCI). The aim of this study was to evaluate the long\u2010term effects after a planned switch from abciximab to eptifibatide during PCI.<\/jats:p><\/jats:sec><jats:sec><jats:title>Hypothesis:<\/jats:title><jats:p>A switch from the general use of abciximab to eptifibatide as a GP IIb\/IIIa in connection with PCI would not have any negative effects on long\u2010term clinical outcomes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p>To reduce costs, a general switch from abciximab to eptifibatide was instituted in 2004 in 2 university hospitals in Sweden. All patients treated 6 months before and 6 months after the switch were followed for 30 months. During the study period, 1038 patients underwent PCI and received a GP IIb\/IIIa receptor inhibitor, 481 (46%) before the switch (Group A) and 557 (54%) after the switch (Group B). The 2 groups had similar baseline characteristics. The primary endpoint was the composite of death, myocardial infarction, stroke, or new coronary revascularization (percutaneous or surgical); secondary endpoints were the individual components of this composite. A separate analysis was performed on patients treated for ST\u2010segment elevation myocardial infarction, non\u2013ST\u2010segment elevation myocardial infarction\/unstable angina, and diabetes, respectively. Data were collected from the Swedish Coronary Angiography and Angioplasty Registry.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p>There were no differences between the groups in the primary endpoint (29.7% in Group A vs 29.3% in Group B; <jats:italic>P<\/jats:italic> = 0.48) or in any of the secondary endpoints.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions:<\/jats:title><jats:p>A switch from the general usage of abciximab to eptifibatide as a GP IIb\/IIIa receptor inhibitor in connection with PCI did not seem to have any negative effects on long\u2010term clinical outcomes. Copyright \u00a9 2008 Wiley Periodicals, Inc.<\/jats:p><jats:p>The authors have no funding, financial relationships, or conflicts of interest to disclose.<\/jats:p><\/jats:sec>","DOI":"10.1002\/clc.20814","type":"journal-article","created":{"date-parts":[[2010,11,18]],"date-time":"2010-11-18T18:22:21Z","timestamp":1290104541000},"page":"686-692","source":"Crossref","is-referenced-by-count":5,"title":["Long\u2010Term Results Following Switch From Abciximab to Eptifibatide During Percutaneous Coronary Intervention"],"prefix":"10.1002","volume":"33","author":[{"given":"Michael","family":"Koutouzis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Lagerqvist","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonas","family":"Oldgren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Axel","family":"\u00c5kerblom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magnus","family":"Wahlin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Karlsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Per","family":"Albertsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G\u00f6ran","family":"Matejka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars","family":"Grip","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2010,11,18]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199907293410503"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(01)01423-1"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(02)02666-9"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2007.10.001"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2007.09.012"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2005.11.025"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa013404"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200106213442503"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.285.19.2468"},{"key":"e_1_2_6_11_2","unstructured":"ZeymerU. Eptifibatide versus abciximab in primary PCI for ST\u2010elevation myocardial infarction. EVA\u2010AMI trial.http:\/\/scientificsessions.americanheart.org\/includes\/pdfs\/evaAmifinal.pdf. Accessed November 4 2007."},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1067\/mhj.2001.113391"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200106213442502"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2008.03.008"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa067722"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1G129"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2007.00257.x"},{"key":"e_1_2_6_18_2","first-page":"611","article-title":"Superior in\u2010hospital and 30\u2010day outcomes with abciximab versus eptifibatide: a contemporary analysis of 495 consecutive percutaneous coronary interventions","volume":"16","author":"Deliargyris EN","year":"2004","journal-title":"J Invasive Cardiol"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(03)90029-4"},{"key":"e_1_2_6_20_2","first-page":"809","article-title":"Switching from abciximab to eptifibatide for percutaneous coronary interventions: a local analysis (SWAP study)","volume":"19","author":"Leung VW","year":"2003","journal-title":"Can J Cardiol"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199404073301402"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199706123362401"},{"key":"e_1_2_6_23_2","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0140-6736(98)06113-3","article-title":"Randomized placebo\u2010controlled and balloon angioplasty\u2010controlled trial to assess safety of coronary stenting with use of platelet glycoprotein\u2010IIb\/IIIa blockade","volume":"352","year":"1998","journal-title":"Lancet"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.108.818617"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.293.14.1759"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehl472"}],"container-title":["Clinical Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fclc.20814","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/clc.20814","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T20:38:12Z","timestamp":1700599092000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/clc.20814"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11]]},"references-count":25,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2010,11]]}},"alternative-id":["10.1002\/clc.20814"],"URL":"https:\/\/doi.org\/10.1002\/clc.20814","archive":["Portico"],"relation":{},"ISSN":["0160-9289","1932-8737"],"issn-type":[{"value":"0160-9289","type":"print"},{"value":"1932-8737","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,11]]}}}